English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, June 12, 2023
エーザイ、米国FDA諮問委員会は全会一致でアルツハイマー病治療薬「LEQEMBI(R)」(レカネマブ)の臨床上のベネフィットを支持
Thursday, June 8, 2023
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、韓国において早期アルツハイマー病に係る適応で新薬承認を申請
Friday, June 2, 2023
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
Friday, May 26, 2023
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Wednesday, November 2, 2022
Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination
Monday, October 31, 2022
エーザイ、「アリセプト(R)」について日本のレビー小体型認知症に係る適応に関する再審査結果に伴う用法・用量の一部変更申請の予定について発表
Tuesday, October 4, 2022
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
エーザイ、川島工園において新注射剤棟/研究棟が竣工
Wednesday, September 28, 2022
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575